2,356 results on '"Novartis Pharmaceuticals Corp."'
Search Results
2. Study Data from Vanderbilt University Update Knowledge of Cell Therapy (Chimeric Antigen Receptor T-cell Therapy Yields Similar Outcomes In Patients With and Without Cytokine Release Syndrome)
3. Lupin receivesUS FDA approval for midostaurin capsules
4. Longer-term Novartis Kisqali NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
5. Longer-term Novartis Kisqali(R) NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
6. Longer-term data for Novartis Scemblix(R) reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
7. FORM 8-K: PTC THERAPEUTICS, INC. Files Current Report (Dec 02, 2024)
8. 8-K: PTC THERAPEUTICS, INC
9. PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
10. 10-Q: CARISMA THERAPEUTICS INC
11. Novartis Kesimpta six-year efficacy data show substantial benefits in recently diagnosed treatment-naive people with relapsing multiple sclerosis
12. Findings from Novartis Pharmaceuticals Corporation Provide New Insights into Obesity, Fitness and Wellness (Where Are the Data To Assess the Safety of Paternal Drug Exposure? a Systematic Review of Secondary Databases: a Contribution From Imi ...)
13. New Findings in Gene Therapy Described from Novartis Pharmaceuticals Corporation (Adeno-associated Virus Serotype 2 Capsids With Proteolytic Cuts By Trypsin Remain Intact and Potent)
14. Novartis Scemblix(R) FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
15. Novartis oral Fabhalta (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
16. Novartis oral Fabhalta(R) (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
17. Novartis ribociclib (Kisqali) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
18. Novartis ribociclib (Kisqali(R)) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R))
19. Novartis receives positive CHMP opinion for Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
20. Novartis receives positive CHMP opinion for Kisqali(R) to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
21. FDA approves Novartis Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer
22. FDA approves Novartis Kisqali(R) to reduce risk of recurrence in people with HR+/HER2- early breast cancer
23. Novartis Kisqali(R) shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
24. Novartis twice-yearly* Leqvio(R) demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
25. Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
26. Novartis receives FDA accelerated approval for Fabhalta (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
27. Novartis receives FDA accelerated approval for Fabhalta(R) (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
28. Alembic Pharmaceuticals receives USFDA approval for Sacubitril and Valsartan Tablets
29. New Stomach Cancer Research from Medical Oncology Unit Described (EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol)
30. Reports Outline Multiple Sclerosis Findings from Missouri Baptist Medical Center (Patient and Physician Perspectives of Treatment Burden In Multiple Sclerosis)
31. Oregon Health & Science University (OHSU) Researcher Describes Research in Ankylosing Spondylitis (A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment)
32. Novartis receives FDA accelerated approval for Fabhalta® iptacopan, the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy IgAN
33. Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
34. 8-K: LEXICON PHARMACEUTICALS, INC
35. FORM 8-K: Carisma Therapeutics Inc. Files Current Report (Jul 02, 2024)
36. 8-K: Carisma Therapeutics Inc
37. Court Rules In Favor Of Manufacturers In 340B Drug Shipment Case
38. Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
39. Alembic Pharma gets USFDA's final nod for Sacubitril and Valsartan tablets
40. Novartis presents latest Phase III Fabhalta (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
41. Novartis Pharmaceuticals Corporation Researchers Update Knowledge of Urticaria (Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous ...)
42. Q3 2023 Legend Biotech Corp Earnings Call - Final
43. Findings from Cleveland Clinic in the Area of Multiple Sclerosis Reported (Effects of Baseline Age and Disease Duration On the Efficacy and Safety of Siponimod In Patients With Active Spms: Post Hoc Analyses From the Expand Study)
44. Reports from Novartis Pharmaceuticals Corporation Provide New Insights into Gene Therapy (Direct Deamidation Analysis of Intact Adeno-associated Virus Serotype 9 Capsid Proteins Using Reversed-phase Liquid Chromatography)
45. Regulatory update: United States Nuclear Regulatory Commission has submitted (Califre R M ) Novartis Pharma Inc., Amend, dtd 1|5|00
46. Legal Research Commentary: United States District Court Northern District of West Virginia 19-201: Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc
47. Novartis Kesimpta(r) six-year efficacy data show substantial benefits in recently diagnosed treatment- naive people with relapsing multiple sclerosis
48. Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naive people with relapsing multiple sclerosis
49. New Novartis Fabhalta(r) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
50. New Novartis Fabhalta (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.